A phase 2 global study revealed that efdoralprin alfa, a new recombinant protein therapy, significantly outperforms the standard plasma-derived treatment in increasing and maintaining functional alpha-1 antitrypsin (fAAT) levels in patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema. Efdoralprin alfa dosed every three weeks maintained normal protective protein levels 100% of the time over 32 weeks, compared to 41% with standard therapy, potentially offering less frequent dosing and better lung protection. The therapy was well tolerated with a safety profile comparable to existing treatments. Sanofi plans to engage with regulators for next steps, with efdoralprin alfa holding fast track and orphan drug designations in the US and EU.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
